Adaptive Biotechnologies Corp (ADPT): Gross Profit
$205.62M
Year ended 2025-12-31
$232.83M
Trailing 12 months to 2026-06-30
+17.3%
3-year compound annual growth
+22.1%
5-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $205.62M | +92.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $106.88M | +12.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $94.72M | -25.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $127.40M | +21.3% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $105.04M | +38.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $75.85M | +20.8% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $62.80M | +74.5% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $35.99M | +58.1% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $22.77M | n/a | 2020-02-26, From 2017-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $205.62M | +92.4% |
| Vericel Corp (VCEL) | 2025-12-31 | $205.60M | +19.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $90.32M | +27.5% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $191.00M | +43.2% |
| REGENXBIO Inc. (RGNX) | 2024-12-31 | $49.76M | -6.2% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $292.76M | +33.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $386.25M | +40.6% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | -$20.98M | n/m |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $3.73M | -72.6% |
Compare ADPT, VCEL, IOVA, TWST side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗